<< Opexa Therapeutics to discuss on personalized medicine for treatment of MS | Sebelius: Department to implement temporary high risk pool program >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Nederlands | Bahasa | Norsk | Русский | Svenska | Polski

Rebirth of the cursed drug Thalidomide

Published on April 5, 2010 at 3:45 AM · No Comments

By Dr Ananya Mandal

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

Now reports have emerged this Sunday of its utility in a rare hereditary blood disorder called hereditary haemorrhagic telangiectasia, or HHT, which causes frequent, hard-to-treat nosebleeds. The occurrence of this disease is really rare with only one in 10,000 getting it.

Research on Thalidomide has for many years been concentrated on its utility in other diseases like Amyotrophic lateral sclerosis, Behcet's syndrome, Brain, Breast and Colorectal cancer, Congestive heart failure, Crohn's disease, HIV infections, Hodgkin's disease, Kaposi's sarcoma, Leukaemia, Myelofibrosis, Myeloid leukaemia and Non-Hodgkin's lymphoma.

Since then a drug with similar chemical structure called Revlimid was made by US ‘pharma’ company Celgene and approved for use in multiple myeloma.

Researchers in France have shown that genetically engineered mice who had HHT showed beneficial results when given Thalidomide. There was a reduced risk of bleeding and blood vessels were better stabilized with Thalidomide. According to the scientists from the National Institute of Health and Medical Research (INSERM) as they report in the journal Nature Medicine, Thalidomide acts here by improving a protein called PDGF-B.

Franck Lebrin, one of the lead researchers of this study said "Biopsies of the nasal surface tissue from patients with HHT showed that similar mechanisms may explain the effects of thalidomide treatment in humans."

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading